|
|
|
| Analysis of Factors Influencing the Efficacy of Azithromycin Sequential Therapy in Children with Mycoplasma Pneumoniae Pneumonia |
| LIU Yuanchao, LI Huanhuan, ZHANG Shouting |
| Department of Pediatrics, Luoning County Chengjiao Township Health Center, Luoning Henan 471700 |
|
|
|
|
Abstract 【Objective】To explore the clinical efficacy of sequential azithromycin therapy in the treatment of Mycoplasma pneumoniae pneumonia (MPP) in children. 【Methods】A total of 126 children with MPP diagnosed and treated in our hospital from June 2022 to July 2024 were selected and divided into the effective group (n=98) and the ineffective group (n=28) according to the therapeutic effect of the children. The general information, laboratory tests and imaging examination results of the two groups of children were compared. 【Result】The duration of fever in the effective group was shorter than that in the ineffective group. The hypersensitive C-reactive protein (hs-CRP), clinical pulmonary infection score (CPIS), and pediatric critical illness score (PCIS) in the effective group were lower than those in the ineffective group. The incidence of circulatory system complications and the infection rate of multiple bacteria in the effective group were lower than those in the ineffective group. The differences were statistically significant (P<0.05). The results of multivariate Logistic regression analysis showed that the duration of fever, circulatory system complications, hs-CRP, and PCIS were the influencing factors of the therapeutic effect of sequential azithromycin therapy in children with MPP (P<0.05). The area under the receiver operating characteristic (ROC) curve (AUC) of the combined prediction of fever duration, circulatory system complications, hs-CRP and PCIS for children who were ineffective azithromycin sequential therapy was 0.956, with a sensitivity of 85.7% and a specificity of 99.0%. 【Conclusion】The duration of fever, circulatory system complications, hs-CRP, and PCIS are the influencing factors of the therapeutic effect of sequential azithromycin therapy in children with MPP. Clinically, these factors should be comprehensively considered to formulate individualized treatment plans to improve the therapeutic effect of patients.
|
|
Received: 28 August 2024
|
|
|
|
|
|
[1] 杨钦,德吉卓嘎,谌亮,等.莨菪碱注射液辅助阿奇霉素序贯治疗小儿支原体肺炎的疗效研究[J].中国现代医学杂志,2020,30(21):74-77.
[2] 吴兴国,杨秀红.布地奈德雾化吸入联合阿奇霉素序贯疗法对小儿支原体肺炎的应用效果分析[J].中国防痨杂志,2024,46(z1):132-134.
[3] 郑武田,方辉,魏守缙,等.维生素C辅助阿奇霉素序贯疗法治疗肺炎支原体肺炎儿童的疗效[J].西北药学杂志,2024,39(4):126-129.
[4] 余廷英.阿奇霉素序贯疗法治疗小儿支原体肺炎临床疗效与对小儿呼吸系统的影响分析[J].中国防痨杂志,2024,46(z1):197-199.
[5] 罗洪霞,李波,李洪刚,等.双歧杆菌三联活菌肠溶胶囊联合阿奇霉素序贯疗法治疗对肺炎支原体肺炎腹泻患儿胃肠炎症的调节作用[J].中南医学科学杂志,2023,51(1):139-141.
[6] 中华人民共和国国家健康委员会,国家中医药局.儿童社区获得性肺炎诊疗规范(2019年版)[J].中华临床感染病杂志,2019,12(1):6-13.
[7] MIYASHITA N. Atypical pneumonia: Pathophysiology, diagnosis, and treatment[J].Respir Investigat,2022, 60(1): 56-67.
[8] 阎进晓,郭静娜,孙苗,等.阿奇霉素序贯疗法联合复可托对小儿肺炎支原体感染的疗效及GSH-Px、ICAM-1水平的影响分析[J].贵州医药,2022,46(10):1542-1544.
[9] 王勇,王臻颉.喜炎平联合阿奇霉素序贯治疗小儿支原体肺炎的疗效及对微炎症状态和免疫指标的影响[J].中南医学科学杂志,2022,50(5):740-743.
[10] 李珊珊,张云沛,刘晓锡.加味麻杏石甘汤联合阿奇霉素序贯疗法治疗小儿支原体肺炎患儿的疗效及对血清炎症因子、氧化应激反应的影响[J].临床和实验医学杂志,2023,22(8):870-875.
[11] 邱潇,董玉斌,曹亚芹. PDW、D-D、miR-223表达与重症MPP患儿病情及预后的相关性[J].分子诊断与治疗杂志,2025,17(2):275-278.
[12] 李静,杨静容,李亚兰,等.小儿肺炎支原体肺炎血清CRPPCT及ESR水平与MPP病情严重程度的关系[J].西部医学,2021,33(9):1374-1378.
[13] 黄坤玲,路素坤,孙玲,等.儿童肺炎支原体细支气管炎临床特征分析[J].中华实用儿科临床杂志,2022,37(12):909-913.
[14] 韩雪青,胡婷婷,张燕娇,等.难治性小儿支原体肺炎特点及危险因素分析[J].传染病信息,2021,34(5):452-455.
[15] 周宇阳,杨军杰.α1-AT/DNaseⅠ、HBD-1、SF在重症儿童社区获得性肺炎患儿中的表达及其临床意义[J].医学临床研究,2023,40(8):1211-1213.
[16] 秦俊峰,徐国超,安云英,等. 清宣止咳颗粒联合西药治疗肺炎支原体肺炎的临床疗效及对患儿肺功能、免疫功能的影响[J].医学临床研究,2024,41(2):269-272.
|
|
|
|
2025, Vol. 42 
